IPCA Labs Q4 Consol PAT Plummets 22% Y-o-Y to Rs 60 Cr

IPCA Laboratories reported a 22.12% decline in its consolidated net profit of 59.59 crore rupees on Wednesday for the quarter ended March 2024 compared to 76.52 crore rupees in the corresponding quarter FY 2023.

Key Takeaways from IPCA Lab’s Performance:

• IPCA Labs reported a consolidated net profit of 59.59 crore rupees, down 22.12%. 
• Revenue from operations jumped to 34.49% on year to 2,033.01 crore rupees.
• The company’s EBITDA stood at 304.59 crore rupees, a 78% on-year growth.
• The board recommended a final dividend of Rs 2 per share for FY24.

Sequentially, profit before tax tumbled 40.82% to 76.60 crore rupees in the March quarter from 129.44 crore rupees posted in Q4 FY23.

However, revenue from operations jumped to 34.49% on year to 2,033.01 crore rupees in the quarter ended March 2024.

Further, EBITDA (earnings before interest, tax, depreciation and amortisation) stood at 304.59 crore rupees, registering a 78% on-year growth.

Meanwhile, the company’s board has recommended a final dividend of Rs 2 per share for the financial year ending 2023-24.

About IPCA Laboratories Limited:

 IPCA established in 1949, is a pharmaceutical company with a strong thrust on exports which now account for nearly 50% of the company's income. IPCA produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, the company has been a crucial healthcare partner in over 120 countries across the globe.

Read More About IPCA Laboratories Limited Share Price Here!